“GLP-1RAs Linked to Lower Adverse Cardiovascular Events, Mortality in NAFLD and Type 2 Diabetes Patients vs Metformin and Other Glucose-Lowering Meds, but Not SGLT2 Inhibitors”

https://pubmed.ncbi.nlm.nih.gov/38117293

In individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse cardiovascular events and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications, but not when compared with SGLT2 inhibitors.